Herceptin filed for gastric cancer in Japan
This article was originally published in Scrip
Executive Summary
Roche's subsidiary Chugai has filed for the Japanese approval of Herceptin (trastuzumab) in combination with the oral chemotherapy drug Xeloda (capecitabine) for the treatment of HER2-positive advanced or recurrent gastric cancer.